Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model

被引:45
作者
Ahmed, S [1 ]
Johnson, CS
Rueger, RM
Trump, DL
机构
[1] Univ Pittsburgh, Sch Med, Inst Canc, Dept Med, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol, Pittsburgh, PA USA
[3] Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol, Pittsburgh, PA USA
关键词
prostate; prostatic neoplasms; vitamin D; mitoxantrone; dexamethasone;
D O I
10.1016/S0022-5347(05)64740-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Mitoxantrone combined with glucocorticoids is widely used for androgen independent prostate cancer. It is well tolerated, reduces prostate specific antigen, diminishes pain and improves quality of life. Calcitriol (1,25-dihydroxycholecalciferol) inhibits proliferation, modulates cell cycle progression, induces apoptosis and potentiates the cytotoxic effects of a number of agents. Glucocorticoids potentiate the antitumor effects of calcitriol and blunt calcitriol induced hypercalcemia. Therefore, we investigated the effect of calcitriol on the antitumor efficacy of mitoxantrone and dexamethasone or mitoxantrone/dexamethasone in the PC-3 androgen independent prostate cancer model. Materials and Methods: We treated PC-3 cells in vitro with various concentrations of mitoxantrone/dexamethasone with and without calcitriol, and assessed growth inhibition by crystal violet assays. We similarly treated mice bearing PC-3 xenografts and performed excision clonogenic assays and tumor outgrowth studies to assess antitumor activity. Results: Calcitriol significantly increased mitoxantrone/dexamethasone mediated growth inhibition in PC-3 cells (p <0.05). Median dose effect analysis indicated that calcitriol is synergistic with mitoxantrone. Adding calcitriol to mitoxantrone/dexamethasone significantly reduced the surviving fraction per gm. tumor compared with mitoxantrone/dexamethasone or untreated controls (P <0.03). Calcitriol plus mitoxantrone/dexamethasone also caused significantly greater tumor regression in PC-3 xenografts compared with treatment with mitoxantrone/dexamethasone or untreated controls (p <0.02). Conclusions: These preclinical data demonstrate that calcitriol increases the antitumor activity of mitoxantrone/dexamethasone in the PC-3 model system. This combination may be efficacious for prostate cancer.
引用
收藏
页码:756 / 761
页数:6
相关论文
共 33 条
[1]  
BEER TM, 2002, P AM SOC CLIN ONCOL
[2]   The vitamin D3 analog, ILX-23-7553, enhances the response to Adriamycin and irradiation in MCF-7 breast tumor cells [J].
Chaudhry, M ;
Sundaram, S ;
Gennings, C ;
Carter, H ;
Gewirtz, DA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (05) :429-436
[3]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[4]   Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy:: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group [J].
Fosså, SD ;
Slee, PHT ;
Brausi, M ;
Horenblas, S ;
Hall, RR ;
Hetherington, JW ;
Aaronson, N ;
de Prijck, L ;
Collette, L .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :62-71
[5]  
GACZYNSKI M, 1990, CANCER RES, V50, P1183
[6]   Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system [J].
Getzenberg, RH ;
Light, BW ;
Lapco, PE ;
Konety, BR ;
Nangia, AK ;
Acierno, JS ;
Dhir, R ;
Shurin, Z ;
Day, RS ;
Trump, DL ;
Johnson, CS .
UROLOGY, 1997, 50 (06) :999-1006
[7]  
Hershberger PA, 1999, CANCER RES, V59, P2644
[8]  
Hershberger PA, 2001, CLIN CANCER RES, V7, P1043
[9]   SYNERGISTIC ENHANCEMENT BY INTERLEUKIN-1-ALPHA OF CISPLATIN-MEDIATED ANTITUMOR-ACTIVITY IN RIF-1 TUMOR-BEARING C3H/HEJ MICE [J].
JOHNSON, CS ;
CHANG, MJ ;
YU, WD ;
MODZELEWSKI, RA ;
GRANDIS, JR ;
VLOCK, DR ;
FURMANSKI, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (05) :339-346
[10]   Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study [J].
Kantoff, PW ;
Halabi, S ;
Conaway, M ;
Picus, J ;
Kirshner, J ;
Hars, V ;
Trump, D ;
Winer, EP ;
Vogelzang, NJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2506-2513